Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Astellas Pharma Inc. ADR | Zolbetuximab in combination with pembrolizumab - (LUCERNA) | Advanced unresectable or metastatic gastric or GEJ adenocarcinoma | Phase 3 | Ongoing | Intravenous | Oncology |
| Astellas Pharma Inc. ADR | PADCEV (enfortumab vedotin) - (EV-202) | Solid tumors, non-squamous and squamous non–small cell lung cancer | Phase 2 | Ongoing | Intravenous | Oncology |
| Astellas Pharma Inc. ADR | Zolbetuximab - (ILUSTRO) | First-line advanced gastric and gastroesophageal junction (GEJ) cancer | Phase 2 | Ongoing | Intravenous | Oncology |
| Astellas Pharma Inc. ADR | Avacincaptad pegol (Zimura) | Wet age-related macular degeneration (Wet-AMD) | Phase 2a | Intravitreal injection | Opthalmic | |
| Astellas Pharma Inc. ADR | Zimura - (STAR) | Autosomal Recessive Stargardt Disease | Phase 2b | Intravitreal | Genetic Disorder | |
| Astellas Pharma Inc. ADR | Fezolinetant - (DAYLIGHT) | Severe vasomotor symptoms (VMS) due to menopause | Phase 3 | Data Released | Oral | Women's Health |
| Astellas Pharma Inc. ADR | Fovista | Wet age-related macular degeneration (Wet-AMD) | Phase 3 | Intravitreal injection | Opthalmic | |
| Astellas Pharma Inc. ADR | Zolbetuximab + CAPOX - (GLOW) | Claudin-18 isoform 2-positive (CLDN18.2)+, HER2‚àí, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma | Phase 3 | Data Released | Intravenous | Oncology |
